Navigation Links
PROMACTA(R) (eltrombopag) RECEIVES UNANIMOUS RECOMMENDATION BY FDA ADVISORY PANEL
Date:5/30/2008

n, affecting less than 200,000 individuals in the United States.(1)

Eltrombopag is an investigational, once-daily oral treatment developed to induce the production of cells in the bone marrow to increase platelets, which are critical in minimizing the incidence of bleeding in chronic ITP.

Eltrombopag, a novel oral thrombopoeitin (TPO) receptor agonist, if approved, would be the first oral short-term treatment of previously treated patients with chronic ITP to increase platelet counts and reduce or prevent bleeding.

In the pivotal studies, the most common adverse events observed in patients taking eltrombopag were headache, nasopharyngitis, and nausea.

About the data

The NDA submission is supported by the largest database of clinical trial information on investigational therapies for chronic ITP patients. Two pivotal trials (one Phase III trial and one Phase II trial), were submitted to support the filing.

About ITP

Chronic ITP is a disorder marked by increased platelet destruction and/or inadequate platelet production in the blood, which causes an increased risk of bruising and bleeding.(2,3) There are estimated to be approximately 60,000 individuals diagnosed with chronic ITP in the U.S.(4) People with chronic ITP often bleed from small blood vessels causing bruises, nosebleeds or even fatal gastrointestinal or intra cerebral bleeds, although these are rare.(3)

About Eltrombopag

Eltrombopag is an oral, non-peptide thrombopoietin receptor agonist that has been shown in pre-clinical research and clinical trials to stimulate the proliferation and differentiation of megakaryocytes, the bone marrow cells that give rise to blood platelets. Eltrombopag was discovered as a result of research collaboration between GlaxoSmithKline and Ligand Pharmaceuticals (Nasdaq:

SOURCE GlaxoSmithKline
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4

Related medicine news :

1. GlaxoSmithKline Files for FDA Approval of PROMACTA(TM) (eltrombopag) to be the First Oral Platelet Growth Factor for Rare Blood Disorder
2. Lake Elsinore Family Caregiver Receives Free Power Wheelchair From The SCOOTER Store
3. DaVita Receives Civil Complaint
4. Ranbaxy Receives Tentative Approval to Manufacture and Market Galantamine Tablets on an Exclusive Basis
5. Watson Receives First FDA Approval for Manufacturing Product at Its Goa, India Facility
6. Edwards Lifesciences Receives CE Mark for Edwards SAPIEN Transcatheter Heart Valve
7. PainCare Receives $14.4 Million in Cash From Completed Sale of South Florida Ambulatory Surgery Centers
8. UT Southwesterns obesity research receives $22 million NIH Roadmap grant
9. Temple Emergency Medicine receives $1.8M to find best MRSA treatment
10. Prime Therapeutics Receives TIPPS Certification
11. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... Children had half as many emergency department ... hours on five or more days a week, according ... Mott Children,s Hospital and Johns Hopkins University. , The ... The Journal of Pediatrics and will be presented ... are an important step in understanding where primary care ...
(Date:6/19/2013)... Casual, no-strings sexual encounters are increasingly common on ... than others to "hook up"? A new study ... Behavioral and Preventive Medicine, published online by the ... are certain factors and behaviors associated with sexual ... "Given the potential for negative emotional and physical ...
(Date:6/19/2013)... block the body,s system for repairing damage to the ... unlikely as it may seem, those compounds are sparking ... driven by a mutation in BRCA, a gene that ... the mutation. The compounds, termed PARP inhibitors, are the ... of Chemical & Engineering News . C&EN is ...
(Date:6/19/2013)... at Louisiana State University have developed a method for ... relies on understanding the genetic interaction between single nucleotide ... prostate cancer,s aggressiveness to avoid unnecessary radical treatment. ... PLOS ONE in April. , According to ... all cancers and 9 percent of cancer deaths. It ...
(Date:6/19/2013)... June 19, 2013 Alternatives, a revolutionary ... patients to quit using drugs while allowing them to ... the founders of Alternatives, believe that abstinence-only approaches force ... enter treatment and that this approach hurts instead of ... in the United States need treatment for addiction but ...
Breaking Medicine News(10 mins):Health News:Extended primary care office hours might help keep kids out of the emergency department 2Health News:Why are some college students more likely to 'hook up'? 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3
... effect of tiny nanoparticles on the health of the ... exhaust and are also used in making household goods ... scientists will assess if these particles damage liver cells. ... times smaller than the width of a human hair, ...
... Harris Interactive? for the Vagisil Women's Health CenterSM conducted a ... of today's American women are taking active roles in their ... thirds of women aged 18 and older (63 percent) report ... go to a gynecologist, 61 percent say they "always" go ...
... London. The overseas doctors in Britain are alarmed as new ... work permit before they can work// in hospitals of ... thousands of doctors from the Indian subcontinent who ... job vacancy if there are no local doctors available the ...
... afflict anyone, even the health conscious, but dying from ... study//. To make this happen, it would obviously warrant ... adopting nutritious food habits, regular exercise, and screenings as ... enabled by the American Cancer Society. ,Vilma ...
... the survey conducted by the Scottish executives large numbers of ... drinking. The researchers feel that memory loss is associated with ... vulnerable situations, becoming a target for rapists. ,This ... large percentage was losing their memories as a result of ...
... provided some useful tips on prevention of skin cancer ... risk factors and treatment. ,According to them ... skin cancer individuals who have a family history of ... because of certain inherited chromosomes and gene mutations. The ...
Cached Medicine News:Health News:Women aware of “feminine health” : their attitud 2Health News:Work Permit Required For Indian Doctors in Britain 2Health News:Work Permit Required For Indian Doctors in Britain 3Health News:Did You Know That 50% Of Deaths Due To Cancer, Can be Prevented? 2Health News:Prevent Skin Cancer with Lifestyle Changes 2
(Date:6/18/2013)... Ill. , June 18, 2013 /PRNewswire-iReach/ -- ... its new X3130 Appliance Inlet Module. The X3130, ... breaker , combines a C14 appliance inlet module, ... compact package.  This three-in-one device allows design engineers ... designs - cutting installation time by 66 percent ...
(Date:6/18/2013)... , June 18, 2013  It has become ... Alliance Seating and Mobility, a subsidiary company of ... timely repair. This appears to be due to ... of field service employees.  (Logo: ... many of these clients are complex mobility users ...
(Date:6/18/2013)...  Recent regulatory and budget challenges have made it ... large pharmaceutical companies to effectively educate doctors and other ... their new products. With the pressure to reduce budgets ... these "Med Ed" groups find practical, economical ... the changes that are transforming the Medical Education area ...
Breaking Medicine Technology:Three-in-One X3130 Appliance Inlet Module 2Though Vital to Educating Doctors on New Products, Pharma "Med Ed" Groups Working Under Huge Internal & External Constraints 2
... HistoRx, Inc. (privately held), a diagnostics company, announced ... of clinical diagnostic assays based on AQUA® technology. ... specialized laboratory service provider, is launching NexCourse®(1) BCa ... assays based on quantitative immunohistochemistry.  NexCourse BCa by ...
... SHANGHAI, Nov. 12, 2010 /PRNewswire-Asia/ -- WuXi PharmaTech ... announced shareholder resolutions adopted at its annual general ... November 10, 2010. (Logo: http://photos.prnewswire.com/prnh/20040705/CNM002LOGO) ... the meeting, WuXi PharmaTech shareholders approved the re-election ...
Cached Medicine Technology:HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology 2HistoRx Announces First Clinical Diagnostic Use of AQUA® Technology 3WuXi PharmaTech Announces Shareholder Resolutions Adopted at 2010 Annual General Meeting 2
... Size: 3.0 x 7.5 x 80 ... Sponge II line designed by Harvey ... is a closed cell sponge which ... soft with rounded edges to minimize ...
... Size: 4.0 x 80 mm. Storz ... line designed by Harvey A. Lincoff, ... cell sponge which is non-toxic and ... edges to minimize scleral intrusion. These ...
For use with E5381 700 Circling Band (240 style). 1.65 mm diameter, 30.0 mm long....
For use under silicone strips E5381 610, E5381 611 and E5381 710. Indications: When higher buckle is required. Overall length: 6.1 mm....
Medicine Products: